reports
Visioneering Technologies Inc: 1 director
A director at Visioneering Technologies Inc maiden bought 124,872 shares at 0.400AUD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...
Visioneering Technologies obtient la marque CE pour sa gamme de lentil...
ATLANTA--(BUSINESS WIRE)-- Visioneering Technologies, Inc. (ASX : VTI), une société innovante basée aux États-Unis spécialisée dans le développement de produits avancés visant à améliorer la vision, a annoncé aujourd'hui avoir reçu la marque CE européenne (Conformité Européenne) pour la commercialisation dans l'Union européenne de son portefeuille de lentilles de contact journalières exclusives de marque NaturalVue® (etafilcon A), y compris les lentilles Sphere, Toric, Multifocal et Multifocal Toric. La marque CE obtenue par VTI inclu...
Visioneering Technologies Achieves CE Mark for NaturalVue® Family of ...
ATLANTA--(BUSINESS WIRE)-- Visioneering Technologies, Inc. (ASX: VTI), an innovative US-based medical device company dedicated to developing advanced products that improve vision, announced today receipt of the European CE Mark (Conformité Européenne) for commercialization in the European Union of its portfolio of proprietary NaturalVue® (etafilcon A) brand 1 Day Contact Lenses, including Sphere, Toric, Multifocal and Multifocal Toric. VTI’s CE Mark includes an indication for VTI’s unique NaturalVue Multifocal (NVMF) for myopic progre...
Newly Expanded Evidence from Clinical Practice on NaturalVue® (etafil...
ATLANTA--(BUSINESS WIRE)-- Visioneering Technologies, Inc (ASX: VTI), a US-based medical device company (‘Visioneering’ or ‘The Company’) engaged in the design, manufacture, sale and distribution of its proprietary NaturalVue® Multifocal 1 Day (NaturalVue MF) Contact Lenses has today announced data presented at the Global Specialty Lens Symposium (GSLS). The new data highlights the impact of NaturalVue Multifocal on paediatric myopia. Myopia (also known as nearsightedness) is a condition with a rapidly increasing prevalence tha...
Visioneering Technologies, Inc. Expands US Sales Force
ATLANTA--(BUSINESS WIRE)-- Visioneering Technologies, Inc. (ASX: VTI), a US-based medical device company (‘Visioneering’ or ‘The Company’) engaged in the design, manufacture, sale and distribution of its proprietary NaturalVue® Multifocal 1 Day Contact Lenses, is pleased to announce the recent expansion of its US sales force. In line with Visioneering’s plan to broaden and accelerate its US launch of NaturalVue Multifocal Contact Lenses, they have appointed Mr. Joshua Suarez as new District Sales Manager for the western Unite...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.